Reference number
2561-H

SPECIALTY QUANTITY LIMIT PROGRAM

TAVALISSE (fostamatinib disodium hexahydrate)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of chronic or persistent immune thrombocytopenia (ITP) fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Tavalisse (fostamatinib) 100 mg tablets	60 per 30 days	Initiate at 100 mg orally twice daily with or without food. After 4 weeks, increase to 150 mg twice daily, if needed, to achieve platelet count at least 50 x 10^9/L as necessary to reduce the risk of bleeding.
Tavalisse (fostamatinib) 150 mg tablets	60 per 30 days	

III. REFERENCE

1. Tavalisse [package insert]. South San Francisco, CA: Rigel Pharmaceuticals, Inc.; April 2018.